JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Characterization of small extracellular vesicles from ovarian cancer patients and pre-diagnostic patient samples: Evidence from the Danish blood donor study

  • 0Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Plos One +

|

May 15, 2025

|

May 15, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study explored extracellular vesicles (EVs) as potential early biomarkers for ovarian cancer (OC). While EV size heterogeneity was observed in OC patients, specific miRNA biomarkers were not validated for early detection.

Area Of Science

  • Gynecologic Oncology
  • Biomarker Discovery
  • Extracellular Vesicle Research

Background

  • Ovarian cancer (OC) remains a leading cause of gynecologic cancer mortality.
  • Existing OC biomarkers lack sufficient specificity and sensitivity for early detection.
  • Extracellular vesicles (EVs) and their contents (surface proteins, microRNA) show promise as novel biomarkers.

Purpose Of The Study

  • To characterize EVs from ovarian cancer patients, benign tumor patients, and healthy controls.
  • To identify potential early ovarian cancer biomarkers in plasma-derived EVs.
  • To assess EV surface proteins and microRNA profiles for diagnostic potential six months prior to OC diagnosis.

Main Methods

  • Plasma samples from ovarian cancer (OC), benign tumor (B), control (C), and pre-diagnostic (PD) groups were analyzed.
  • Small extracellular vesicles (EVs) were isolated using ultracentrifugation and characterized by Dynamic Light Scattering (DLS), EV Array, NanoFlow Cytometry, Nanoparticle Tracking Analysis, and Western blots.
  • MicroRNA (miRNA) profiling was performed using TaqMan Array Human MicroRNA cards, with validation via RT-qPCR.

Main Results

  • EVs from OC patients exhibited greater size heterogeneity compared to other groups.
  • Key EV proteins CD63 and TSG101 were identified.
  • While initial miRNA analysis suggested differential abundance between OC and B groups, these findings were not reproducible in validation studies.

Conclusions

  • The study characterized EVs in various patient cohorts, including pre-diagnostic cases.
  • Further research is needed to investigate specific EV proteins (e.g., CD9, CD151, CD81) and their combination with established biomarkers (e.g., CA125, HE4) for improved ovarian cancer detection.
  • The potential of EVs as early ovarian cancer biomarkers requires more extensive investigation.